% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gaiser:142358,
      author       = {T. Gaiser and D. Hirsch and A. Orouji and M. Bach and P.
                      Kind and D. Helbig and A. Quaas and J. Utikal$^*$ and A.
                      Marx and M. R. Gaiser$^*$},
      title        = {{MYC} gene amplification is a rare event in atypical
                      fibroxanthoma and pleomorphic dermal sarcoma.},
      journal      = {OncoTarget},
      volume       = {9},
      number       = {30},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2019-00134},
      pages        = {21182-21189},
      year         = {2018},
      abstract     = {Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma
                      (PDS) are rare malignancies typically occurring in elderly
                      patients and predominantly located in skin regions exposed
                      to UV-light. Thus, a role of UV-radiation-induced damage for
                      AFX and PDS tumorigenesis has been postulated. MYC gene
                      amplification has been demonstrated as a distinctive feature
                      of radiation-induced angiosarcoma. In order to investigate
                      whether chronic exposure to UV-light might also lead to MYC
                      copy number changes, 51 AFX and 24 PDS samples were
                      retrospectively analyzed for MYC amplification by
                      fluorescence in situ hybridization using a MYC and a CEP8
                      gene probe. Of the 44 analyzable AFX samples, one case
                      showed MYC amplification (defined as a MYC/CEP8 ratio
                      ≥2.0), whereas 13 cases demonstrated low level copy number
                      gains (defined as MYC/CEP8 ratio ≥ 1.2-< 2.0). MYC
                      amplification was seen in an AFX sample of extraordinary
                      tumor thickness of 17.5 mm (vs. median 3.25 mm for all
                      samples). Of the 24 PDS cases, five specimen demonstrated
                      MYC low level copy number gains. Immunohistochemically,
                      neither the AFX nor the PDS cases showed MYC protein
                      expression. In summary, these findings rule out that MYC
                      amplification is a major genetic driver in the process of
                      AFX or PDS tumorigenesis. However, MYC amplification may
                      occur as a late event during AFX development and hence might
                      only be detectable in advanced, thick lesions.},
      cin          = {G300},
      ddc          = {610},
      cid          = {I:(DE-He78)G300-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29765529},
      pmc          = {pmc:PMC5940384},
      doi          = {10.18632/oncotarget.24997},
      url          = {https://inrepo02.dkfz.de/record/142358},
}